TY - JOUR
T1 - Lewy Body Dementia Association's Research Centers of Excellence Program
T2 - Inaugural Meeting Proceedings
AU - Peterson, Bethany
AU - Armstrong, Melissa
AU - Galasko, Douglas
AU - Galvin, James E.
AU - Goldman, Jennifer
AU - Irwin, David
AU - Paulson, Henry
AU - Kaufer, Daniel
AU - Leverenz, James
AU - Lunde, Angela
AU - McKeith, Ian G.
AU - Siderowf, Andrew
AU - Taylor, Angela
AU - Amodeo, Katherine
AU - Barrett, Matt
AU - Domoto-Reilly, Kimiko
AU - Duda, John
AU - Gomperts, Stephen
AU - Graff-Radford, Neill
AU - Holden, Samantha
AU - Honig, Lawrence
AU - Huddleston, Daniel
AU - Lippa, Carol
AU - Litvan, Irene
AU - Manning, Carol
AU - Marder, Karen
AU - Moussa, Charbel
AU - Onyike, Chiadi
AU - Pagan, Fernando
AU - Pantelyat, Alexander
AU - Pelak, Victoria
AU - Poston, Kathleen
AU - Quinn, Joseph
AU - Richard, Irene
AU - Rosenthal, Liana S.
AU - Sabbagh, Marwan
AU - Scharre, Douglas
AU - Sha, Sharon
AU - Shill, Holly
AU - Torres-Yaghi, Yasar
AU - Christie, Tina
AU - Graham, Todd
AU - Richards, Ian
AU - Koehler, Mike
AU - Boeve, Brad
N1 - Funding Information:
Marwan Sabbagh is currently serving as an investigator for clinical trials sponsored by NIH. He serves on the Scientific Advisory Board of Bracket. He receives research support from NIH. Dr. Sabbagh has ownership interest in Versanum Inc., Brain Health Inc., Optimal Cognitive Health Company, and uMethod. He consults for Neurotrope, Allergan, Biogen, Bracket, Grifols, vTv Therapeutics, Sanofi, Cortexyme, and Roche-Genentech. Douglas Scharre has received consulting from BrainTest, royalty fees from BrainTest for the Self-Administered Gerocognitive Examination (SAGE) licensing, and research support from Avanir, Insightec, Merck, Lilly, Axovant, Neurocentria, Astra-Zeneca, Biogen, Novartis, Neurim, Alzheimer’s Therapeutic Research Institute (ATRI), Harry T. Mangurian Foundation, Alzheimer’s Disease Cooperative Study (ADCS), and Johns Hopkins University. Sharon Sha receives research support from Biogen Idec, F Hoffmann-La Roche Ltd., Genentech, and Novartis for her role as Investigator in Clinical Trials and has received support from Merck and Alkahest for prior trials. She has been a consultant for Abelson Taylor, Baird, Clearview Healthcare Partners, SelfCare Catalysts Inc., and the University of Southern California. She is funded by NIH grants P50 AG047366 (Stanford Alzheimer’s Disease Center) and R01 AG048076-02. Holly Shill has received research support from Biogen; Dong-A ST Co., Ltd.; MagQu. Intec Pharma, Ltd.; US World Meds; and Sunovion/Cynapsus Therapeutics, Inc., and consulting honoraria for advisory boards from Abbvie and Sunovion. Yasar Torres-Yaghi received consulting fees from Abbvie, Sunovion, and Acorda. Tina Christie is an employee of the Lewy Body Dementia Association. Todd Graham is an employee of the Lewy Body Dementia Association. Ian Richards is an employee of the Lewy Body Dementia Association. Mike Koehler is an employee of the Lewy Body Dementia Association. Brad Boeve has served as an investigator for clinical trials sponsored by GE Healthcare, Axovant, and Biogen. He receives royalties from the publication of a book entitled Behavioral Neurology Of Dementia (Cambridge Medicine, 2009, 2017). He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, and the Little Family Foundation.
Funding Information:
This work is supported by the Lewy Body Dementia Association.
Publisher Copyright:
© 2019 The Author(s).
PY - 2019/3/13
Y1 - 2019/3/13
N2 - The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator's meeting was held on December 14, 2017, in New Orleans. The program was established to increase patient access to clinical experts on Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), and to create a clinical trials-ready network. Four working groups (WG) were created to pursue the LBDA RCOE aims: (1) increase access to high-quality clinical care, (2) increase access to support for people living with LBD and their caregivers, (3) increase knowledge of LBD among medical and allied (or other) professionals, and (4) create infrastructure for a clinical trials-ready network as well as resources to advance the study of new therapeutics.
AB - The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator's meeting was held on December 14, 2017, in New Orleans. The program was established to increase patient access to clinical experts on Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), and to create a clinical trials-ready network. Four working groups (WG) were created to pursue the LBDA RCOE aims: (1) increase access to high-quality clinical care, (2) increase access to support for people living with LBD and their caregivers, (3) increase knowledge of LBD among medical and allied (or other) professionals, and (4) create infrastructure for a clinical trials-ready network as well as resources to advance the study of new therapeutics.
KW - Lewy Body Dementia Association
KW - Lewy body dementia
KW - Parkinson's disease dementia
UR - http://www.scopus.com/inward/record.url?scp=85062878475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062878475&partnerID=8YFLogxK
U2 - 10.1186/s13195-019-0476-1
DO - 10.1186/s13195-019-0476-1
M3 - Article
C2 - 30867052
AN - SCOPUS:85062878475
SN - 1758-9193
VL - 11
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 1
M1 - 23
ER -